SillaJen, Inc. is a privately-held biotechnology company focusing on engineering and developing best-in-class oncolytic immunotherapeutics. SillaJen has Korean offices in Pusan (R&D), at Pusan National University (PNU), and in Seoul (finance, management & legal). SillaJen also has Clinical R&D, regulatory affairs and CMC capabilities in San Francisco, California, one of the world’s leading biotechnology centers and the “birthplace” of the biotech industry. SillaJen products are engineered from vaccinia which has unique attributes as an oncolytic immunotherapy.
Looking for a particular SillaJen Inc. employee's phone or email?
The SillaJen Inc. annual revenue was $8 million in 2026.
Nicholas Gaspar is the Director of Clinical Assays of SillaJen Inc..
23 people are employed at SillaJen Inc..
SillaJen Inc. is based in Yeongdeungpo-gu, Seoul.
The NAICS codes for SillaJen Inc. are [3254, 32, 54, 541, 325, 32541].
The SIC codes for SillaJen Inc. are [283, 28].